New York State Common Retirement Fund
SYRE icon

New York State Common Retirement Fund’s Spyre Therapeutics SYRE Stock Holding History

New York State Common Retirement Fund’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Buy
26,165
+3,900
+18% +$285K ﹤0.01% 1407
2026
Q1 		$1.12M Buy
22,265
+3,100
+16% +$117K ﹤0.01% 1624
2025
Q4 		$628K Buy
19,165
+2,600
+16% +$67.9K ﹤0.01% 1884
2025
Q3 		$278K Hold
16,565
– – ﹤0.01% 2152
2025
Q2 		$248K Buy
16,565
+6,300
+61% +$93.2K ﹤0.01% 2162
2025
Q1 		$166K Hold
10,265
– – ﹤0.01% 2307
2024
Q4 		$239K Hold
10,265
– – ﹤0.01% 2224
2024
Q3 		$302K Sell
10,265
-4,100
-29% -$114K ﹤0.01% 2134
2024
Q2 		$338K Sell
14,365
-305
-2% -$10.3K ﹤0.01% 2198
2024
Q1 		$556K Buy
14,670
+14,305
+3,919% +$414K ﹤0.01% 2032
2023
Q4 		$7.86K Buy
+365
New +$5.03K ﹤0.01% 3201
2022
Q3 		– Sell
-14
Closed – – 3439
2022
Q2 		$0 Sell
14
-668
-98% -$23.4K ﹤0.01% 3537
2022
Q1 		$39K Hold
682
– – ﹤0.01% 3216
2021
Q4 		$81K Sell
682
-1
-0.1% -$158 ﹤0.01% 3132
2021
Q3 		$136K Sell
683
-576
-46% -$101K ﹤0.01% 3039
2021
Q2 		$219K Buy
1,259
+15
+1% +$2.73K ﹤0.01% 3012
2021
Q1 		$246K Hold
1,244
– – ﹤0.01% 2756
2020
Q4 		$245K Sell
1,244
-292
-19% -$60.5K ﹤0.01% 2667
2020
Q3 		$272K Hold
1,536
– – ﹤0.01% 2517
2020
Q2 		$355K Buy
1,536
+780
+103% +$149K ﹤0.01% 2389
2020
Q1 		$88K Hold
756
– – ﹤0.01% 2810
2019
Q4 		$144K Sell
756
-312
-29% -$61.2K ﹤0.01% 2884
2019
Q3 		$205K Sell
1,068
-4
-0.4% -$779 ﹤0.01% 2758
2019
Q2 		$184K Buy
1,072
+728
+212% +$126K ﹤0.01% 2865
2019
Q1 		$69K Hold
344
– – ﹤0.01% 3027
2018
Q4 		$64K Hold
344
– – ﹤0.01% 3060
2018
Q3 		$82K Sell
344
-380
-52% -$88.8K ﹤0.01% 3073
2018
Q2 		$191K Buy
+724
New +$178K ﹤0.01% 2895

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

New York State Common Retirement Fund's SYRE Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Spyre Therapeutics (SYRE) stake by 18% in Q2 2026, buying an estimated $285K and bringing the position to 26,165 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

New York State Common Retirement Fund first reported a position in SYRE in Q2 2018 and has held it in 28 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • New York State Common Retirement Fund held 26,165 shares of Spyre Therapeutics worth $2.32M as of Q2 2026.
  • New York State Common Retirement Fund bought 3,900 Spyre Therapeutics shares in Q2 2026, an estimated $285K.
  • Spyre Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1407 holding.
  • New York State Common Retirement Fund first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 28 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.